Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Lisata Therapeutics ( (LSTA) ).
On April 2, 2026, Lisata Therapeutics, Inc., Kuva Labs Inc. and Kuva Acquisition Corp. agreed to extend the deadline for Kuva’s tender offer to acquire all outstanding Lisata common shares under their March 6, 2026 merger agreement. The tender offer commencement date was pushed from April 3, 2026 to April 13, 2026, or another date mutually agreed, providing additional time for the parties to prepare and execute the offer process.
The waiver formalizing this change specifically extends the period in which the offer must be launched from 20 to 26 business days after signing the merger agreement, while leaving all other terms in place. The limited scope of the modification suggests the overall transaction remains on track, though the timing adjustment may affect short-term expectations for Lisata shareholders awaiting liquidity from the contemplated acquisition.
The most recent analyst rating on (LSTA) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
The score is held back primarily by weak financial performance (limited/volatile revenue, persistent losses, and ongoing cash burn), partially offset by a strong technical uptrend and a value-defining acquisition agreement with additional contingent upside. Valuation is neutral-to-weak given negative earnings and no dividend information.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, Inc. is a Delaware-based biopharmaceutical company operating in the therapeutics industry. It focuses on developing and commercializing innovative treatments, positioning itself within a competitive market for advanced medical therapies and related life sciences transactions, including strategic mergers and acquisitions.
The company’s activities often involve complex deal structures with industry and financial partners. Such transactions can materially affect its capital structure, ownership profile and strategic direction, with direct implications for shareholders, potential acquirers and other stakeholders monitoring its corporate developments.
Average Trading Volume: 171,348
Technical Sentiment Signal: Hold
Current Market Cap: $45.34M
See more insights into LSTA stock on TipRanks’ Stock Analysis page.